Genetic Research on Hodgkin Lymphoma
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 335
Special Issue Editors
Interests: clinical onco-hematology; lymphoma; chromosomal instability; telomeres
Special Issues, Collections and Topics in MDPI journals
Interests: cytogenetics; telomere; DNA repair; radiation effects; genotoxic stress
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hodgkin lymphoma (HL) accounts for approximately 10% of all lymphomas and 1% of all cancers in industrial countries. Current treatment of HL results in a very high cure rate (90%), and thus represents the first—and one of the best—examples of successful treatment in oncology today.
HL also affects young patients, and is therefore the object of intense interest amongst oncologists, cytogeneticists, and radiobiologists, insofar as lessons learned from the study of this disease and its treatment may serve as a basis for novel therapeutics and the follow-up of other cancers.
This special issue in Biomedicine, entitled “Genetic Research on Hodgkin Lymphoma”, gathers original research and review papers on the genetic susceptibility and genomic instability in HL, the interaction between tumor cells and microenvironmental cells, the role of viral infections, and their potential implications on new therapeutic strategies in HL.
Prof. Dr. Patrice Carde
Dr. Radhia M'kacher
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hodgkin lymphoma
- Hodgkin Reed-Sternberg cells
- genetic susceptibility
- chromosomal instability
- MSI
- telomeres
- DNA repair
- viral infection
- immunotherapy
- treatment-related toxicity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
